Literature DB >> 9920164

NOR polyagglutination and Sta glycophorin in one family: relation of NOR polyagglutination to terminal alpha-galactose residues and abnormal glycolipids.

G Kuśnierz-Alejska1, M Duk, J R Storry, M E Reid, B Wiecek, H Seyfried, E Lisowska.   

Abstract

BACKGROUND: This report describes the characterization of polyagglutinable red cells (RBCs), identified in two generations of a Polish family. CASE REPORT: Untreated and modified RBCs of the proposita (TS) were tested by serologic methods, using human sera, antibodies, lectins, and inhibitors of agglutination. Moreover, glycophorins were characterized by sodium docecyl sulfate-polyacrylamide gel electrophoresis and Western blotting, and glycolipids were purified, fractionated by thin-layer chromatography, and detected with Ricinus communis agglutinin I (RCA-I, specific for galactose residues) and Griffonia simplicifolia IB4 lectin (GSL-IB4, specific for Gal alpha1-3Gal- structure). Some of the experiments were also performed on RBCs of members of TS's family.
RESULTS: Polyagglutination, found in four members of TS's family, was identified as the second case of an earlier described NOR polyagglutination. The polyagglutination was decreased by treating the RBCs with alpha-galactosidase and was inhibited by a neutral glycolipid fraction from NOR+ RBCs. Detection of neutral glycolipids of TS's RBCs on the thin-layer plate by RCA-I and GSL-IB4 revealed the presence of components that were not detectable in control RBCs. Moreover, Western blotting of RBC membranes from five family members with glycophorin monoclonal antibodies and agglutination assays with anti-St(a) and anti-Dantu sera identified the presence of St(a) glycophorin in four members of the family, two of whom were NOR+ and two NOR-.
CONCLUSION: Our results showed that two rare features of TS's RBCs, NOR polyagglutination and St(a) glycophorin, are inherited independently, and that NOR+ RBCs contain neutral glycolipids with an abnormal oligosaccharide structure, most likely terminated with alpha-galactosyl residues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920164     DOI: 10.1046/j.1537-2995.1999.39199116892.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

Review 1.  Human genetic disorders of sphingolipid biosynthesis.

Authors:  Leonardo Astudillo; Frédérique Sabourdy; Nicole Therville; Heiko Bode; Bruno Ségui; Nathalie Andrieu-Abadie; Thorsten Hornemann; Thierry Levade
Journal:  J Inherit Metab Dis       Date:  2014-08-21       Impact factor: 4.982

2.  Presence of natural anti-Galalpha1-4GalNAcbeta1-3Gal (anti-NOR) antibodies in animal sera.

Authors:  Maria Duk; Elwira Lisowska
Journal:  Glycoconj J       Date:  2006-11       Impact factor: 2.916

3.  A single point mutation in the gene encoding Gb3/CD77 synthase causes a rare inherited polyagglutination syndrome.

Authors:  Anna Suchanowska; Radoslaw Kaczmarek; Maria Duk; Jolanta Lukasiewicz; Dorota Smolarek; Edyta Majorczyk; Ewa Jaskiewicz; Anna Laskowska; Kazimiera Wasniowska; Magdalena Grodecka; Elwira Lisowska; Marcin Czerwinski
Journal:  J Biol Chem       Date:  2012-09-10       Impact factor: 5.157

Review 4.  Lectins as tools in glycoconjugate research.

Authors:  Albert M Wu; Elwira Lisowska; Maria Duk; Zhangung Yang
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

5.  Evaluation of an amino acid residue critical for the specificity and activity of human Gb3/CD77 synthase.

Authors:  Radoslaw Kaczmarek; Katarzyna Mikolajewicz; Katarzyna Szymczak; Maria Duk; Edyta Majorczyk; Anna Krop-Watorek; Anna Buczkowska; Marcin Czerwinski
Journal:  Glycoconj J       Date:  2016-08-18       Impact factor: 2.916

6.  Single nucleotide polymorphisms in A4GALT spur extra products of the human Gb3/CD77 synthase and underlie the P1PK blood group system.

Authors:  Radoslaw Kaczmarek; Katarzyna Szymczak-Kulus; Anna Bereźnicka; Krzysztof Mikołajczyk; Maria Duk; Edyta Majorczyk; Anna Krop-Watorek; Elżbieta Klausa; Joanna Skowrońska; Bogumiła Michalewska; Ewa Brojer; Marcin Czerwinski
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.